DarioHealth (NASDAQ: DRIO), a leader in the global digital therapeutics (“DTx”) market, reported on new clinical research at the American Diabetes Association (“ADA”)
Scientific Sessions, the premier diabetes conference. The company’s research evaluated the impact of the company’s artificial intelligence (“AI”)-driven personalization engine on user engagement and clinical outcomes; the company’s study involved almost 10,000 users who were involved with a new product experience designed to drive better health habits and behaviors. The results of the company’s research indicate that user engagement increased by 56% and remained consistent at that level for at least six months. The company also presented a second study at the ADA event. That research analyzed the impact of Dario’s hyper-personalization platform on diabetes self-management, evaluating clinical outcomes for more than 11,000 high-risk Type 2 diabetic members after 12 months of engagement. Those results showed that the average ratio of target in-range readings increased significantly from 28.4% to 54.8% and the average number of days between blood glucose readings for Dario members was 3.3 days. “Consistent self-management of health conditions is one of the most crucial healthy behaviors we can help our members develop, and also one of the most difficult,” said DarioHealth scientific and clinical director Yifat Hershcovitz in the press release. “Customizing the experience of health management with real-time data and feedback to offer tangible, actionable insights drives better engagement which leads to positive behavior change and improved clinical outcomes.”
To view the full press release, visit
https://ibn.fm/rQjEj
About DarioHealth Corp.
DarioHealth is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market, covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Dario’s next-generation, AI-powered, digital therapeutic platform supports more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions; intuitive, clinically proven digital tools; high-quality software,;and coaching to help individuals improve health and sustain meaningful outcomes. Dario’s unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology, utilizing a performance-based approach to improve users’ health. On the path to better health, Dario makes the right thing to do the easy thing to do. For more information about the company, please visit
www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at
http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.